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Urokinase-induced smooth muscle cell responses
require distinct signaling pathways: A role for the
epidermal growth factor receptor
Suzanne M. Nicholl, PhD,a Elisa Roztocil, BS,a and Mark G. Davies, MD, PhD,a,b Rochester, NY
Objective: Urokinase plasminogen activator (uPA) a key serine protease during remodeling, is capable of inducing both
smooth muscle cell migration and proliferation. However, the signals that produce these responses are poorly under-
stood.
Methods: Early passage rat aortic arterial smooth muscle cells were cultured in vitro and standard assays of DNA synthesis
([3H]thymidine incorporation), cell proliferation (manual cell counting), and migration (linear wound assay and Boyden
chamber) were used to study the cells responses to uPA. Activation of the mitogen-activated protein kinases (MAPK),
extracellular signal-regulated kinase 1/2 (ERK1/2), p38MAPK, Akt, MAP kinase/ERK kinase (MEK1/2), MAP kinase
kinase (MKK)3/6, and epidermal growth factor receptor (EGFR) in response to uPA was assayed by Western blot
analysis for the phosphorylated form of each kinase. These assays were repeated in the presence of the Gi inhibitor
pertussis toxin (PTx, 100 ng/mL), the Ras inhibitor manumycin A (MA, 10 M), the phosphatidyl-inositol 3= kinase
(PI3K) inhibitor wortmannin (WN, 1 M), the EGFR inhibitor AG1478 (AG, 10 nM), the MEK1 inhibitor PD98059
(PD, 10 M), the p38MAPK inhibitor SB203580 (SB, 10 M), and the plasmin inhibitors aprotinin and -aminocaproic
acid.
Results: uPA induced a twofold increase in smooth muscle cell migration and increased smooth muscle cell DNA synthesis
and proliferation. The ERK1/2 and p38MAPK inhibitors PD98059 (PD) and SB203580 (SB) blocked cell proliferation,
but only PD blocked cell migration. Although uPA-induced phosphorylation of both ERK1/2 and p38MAPK was
blocked by Gi inhibition, inhibition of PI3K and Ras decreased the uPA-induced phosphorylation of ERK1/2 but
not p38MAPK. Activation of MEK1/2 was abrogated by inhibitors of Gi and Ras, but not by PI3K inhibition. In
contrast, activation of MKK3/6 was abrogated by inhibition of Gi, but not by Ras or PI3K inhibition. uPA
induced time-dependent phosphorylation of EGFR, which was dependent on plasmin activity. Inhibition of EGFR
reduced both ERK1/2 and p38MAPK activation. uPA activation of PI3K and MKK3/6 was EGFR-dependent and
that of MEK1 was EGFR-independent.
Conclusion: uPA induces smooth muscle cell proliferation through ERK1/2- and p38MAPK-mediated pathways. Migra-
tion appears to be dependent on ERK1/2 activity alone. Activation of EGFR appears to be required. The differential
activation of pathways for ERK1/2 and p38MAPK by uPA allows for two distinct biologic responses that both require
tyrosine kinase receptor transactivation. (J Vasc Surg 2005;41:672-81.)
Clinical relevance. Elevated urokinase-like plasminogen activator (uPA) and decreased plasminogen activator inhibitor-1
(PAI-1) levels are predictors for restenosis. Matrix remodeling and smooth muscle cell responses are integrally linked.
Changes in smooth muscle cell migration and proliferation are dependent on the extracellular matrix environment in
which they are encased. Proteases such as uPA can effect smooth muscle cells and alter the matrix; their activity is
controlled by a series of inhibitors (eg, PAI-1). The balance of activation and inhibition forms the basis of the proteolytic
thermostat in the vessel wall. Understanding the biology of the proteolytic thermostat will allow for structured
therapeutic interventions to control restenosis and thus improve patient care and avoid secondary interventions. Our
study demonstrates that uPA is capable of inducing separate responses throughmore than one signaling pathway, in part,
by transactivation of a nearby receptor for the unrelated ligand epidermal growth factor receptor (EGFR). Blockade of
EGFR can inhibit both cell migration and proliferation induced by uPA. This is the first description of cross talk between
uPA and EGFR in vascular smooth muscle cells. Targeting a pivotal receptor such as EGFR, which can be transactivated
by both G-protein-coupled receptors and receptor tyrosine kinases, is an attractive molecular target to control restenosis.The universal response of a blood vessel to injury is
chronic wound healing, which includes the development of
intimal hyperplasia through smooth muscle cell migration
and proliferation and subsequent remodeling of the vessel
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restenosis.1 The proliferation and migration of smooth
muscle cells requires the complex regulation of proteases,
integrins, and extracellular molecules.2
The serine protease uPA is the primary plasminogen
activator in tissue remodeling processes. It has both recep-
tor binding and protease properties and is capable of initi-
ating both cell proliferation and migration.3 These re-
sponses involve domain-dependent differential activation
of signaling pathways.3 The protease domain appears re-
sponsible for proliferation, and the growth factor binding
domain initiates migration. The degree to which the mol-
ecule is degraded into its individual domains in vivo is not
known. How the functions of these two domains within an
intact uPA molecule integrate proliferation and migration
of the cell also remains to be defined.
uPA binds to the urokinase plasminogen activator re-
ceptor (uPAR), which is tethered to the membrane by a
glycosyl phosphatidyl inositol (GPI) tail. It is involved in a
multiprotein complex containing integrins, low-density-
lipoprotein–related protein, a G-protein coupled receptor
(FPRL1), and epidermal growth factor receptor (EGFR).4
Interaction with the components of the complex may allow
differential cell signaling.
Both proliferation and migration of cells are dependent
on the activation of the mitogen-activated protein kinases
(MAPKs), extracellular signal-regulated kinase (ERK1/2),
and p38MAPK, which are linked to a cascade of kinases that
transduce and amplify the signal from an activated recep-
tor.5,6 Interaction with the upstream effectors of MAPKs
may modulate the activities of MAPK during migration and
proliferation.
Matrix remodeling and smooth muscle cell responses
are integrally linked. Changes in smooth muscle cell migra-
tion and proliferation depend upon the extracellular matrix
environment in which they are encased. Proteases such as
uPA can effect smooth muscle cells and alter the matrix;
their activity is controlled by a series of inhibitors (eg,
PAI-1). The balance of activation and inhibition forms the
basis of the proteolytic thermostat in the vessel wall.
Understanding the biology of proteolytic thermostat
will allow for structured therapeutic interventions to con-
trol restenosis and thus improve patient care and avoid
secondary interventions. Many previous studies have fo-
cused on the multiple mechanical, humoral, and cellular
elements that induce smooth muscle cell responses (either
migration or proliferation); however, molecular therapeu-
tics focuses on key choke points within the cell that can be
used to inhibit these responses.
The present study examined the pathways that allow
uPA, a plasminogen activator known to be involved in
tissue remodeling after injury, to induce both smooth
muscle cell migration and cell proliferation. Our report
demonstrates that uPA is capable of inducing separate
responses through more than one signaling pathway, in
part, by transactivation of a nearby receptor for an unre-
lated ligand, namely, EGFR. Inhibition of EGFR kinase can
inhibit both cell migration and proliferation induced byuPA. This is the first description of cross talk between uPA
and EGFR in vascular smooth muscle cells. A pivotal recep-
tor such as EGFR, which can be transactivated by both
G-protein-coupled receptors and receptor tyrosine kinases,
is an attractive molecular target to control restenosis.
METHODS
Experimental design. Aortic arterial smooth muscle
cells from male Sprague Dawley rats (250 gm) were cul-
tured in vitro (passages 6 to 10; harvest by the outgrowth
method). Standard assays of DNA synthesis ([3H]thymi-
dine incorporation), cell proliferation (manual cell count-
ing), and migration (linear wound assay and Boyden cham-
ber) were used to study the cell responses to uPA. These
assays were repeated in the presence of the Gi inhibitor
pertussis toxin (PTx, 100 ng/mL), the Ras inhibitor manu-
mycin A (MA, 10M), the phosphatidyl-inositol 3= kinase
(PI3K) inhibitor wortmannin (WN, 1 M), the Src kinase
inhibitor PP2 (10 M), the protein kinase C (PKC) inhib-
itor GF109203X (GFX, 10 M), the EGFR inhibitor
AG1478 (AG, 10 nM), the MAP kinase/ERK kinase
(MEK1) inhibitor PD98059 (PD, 10M), the p38MAPK
inhibitor SB203580 (SB, 10 M), and the plasmin inhibi-
tors aprotinin and ε-aminocaproic acid (Table). Activation
of ERK1/2, p38MAPK, Akt, MEK1/2, MAP kinase kinase
(MKK3/6), and EGFR was assayed by using Western blot
analysis for the phosphorylated form of each kinase. Equal
loading was determined by blotting for the total form of
each kinase.
Materials. Single-chain uPA (sc-uPA) was purchased
from American Diagnostica, Inc, Greenwich, Conn. Per-
tussis toxin and manumycin A were purchased from Sigma
Chemical Co, St. Louis, Mo. GF109203X, AG1478, PP2,
wortmannin, PD98059 and SB203580 were purchased
from Calbiochem, La Jolla, Calif. Peroxidase-conjugated
anti-rabbit immunoglobulin G (IgG) antibody (raised in
goat) was purchased from Jackson ImmunoResearch Lab-
oratories, Inc, West Grove, Pa. Peroxidase-conjugated anti-
mouse IgG antibody (raised in goat) was purchased from
Biorad Laboratories, Hercules, Calif. Phospho-ERK1/2
antibody was purchased from Promega, Inc, Madison, Wis.
Inhibitors used to determine signaling of smooth muscle
cells
Inhibitors
Plasmin ε-aminocaproic acid
Plasmin Aprotinin
Gi G-protein Pertussis Toxin (PTx)
Farnesylation (Ras inhibitor) Manumycin A (MA)
Phosphatidyl-inositol 3’ kinase wortmannin (Wn)
Phosphatidyl-inositol 3’ kinase LY290004 (LY)
Protein Kinase C GF109203X (GFX)
Src Kinase PP2
Epidermal Growth Factor
Receptor kinase
AG1478 (AG)
MEK1/2 PD98059 (PD)
MAPKp38 SB203580 (SB)
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duction Laboratories, Lexington, Ky. Phospho-p38MAPK
antibody was purchased from Biosource, Camarillo, Calif.
Total p38MAPK, phospho-MEK1/2, and phospho-
MKK3/6 antibodies were purchased from Cell Signaling,
Beverley, Mass. Dulbecco’s minimal essential medium
(DMEM) and Dulbecco’s phosphate-buffered saline
(dPBS) were purchased from Cellgro.
Pertussis toxin catalyzes the adenosine diphosphate-
ribosylation of the  subunit of Gi and Go specifically,
preventing coupling with receptors and was used at a
standard inhibitory concentration.7 Pertussis toxin does
not effect Gq, even when modified at its C-terminus to
mimic GI.
Wortmannin specifically inhibits PI3-K at low nanomo-
lar concentrations, and may affect myosin light-chain kinase
at the 10 M dose7; however, it does not inhibit tyrosine
kinases, protein kinase C, or PI4-K.7 Wortmannin has been
demonstrated to inhibit PI3-K activity and Akt phosphor-
ylation at 1M in vascular smooth muscle cells,7 and our
own data on Akt phosphorylation confirmed its effective-
ness at this dose.
LY294002 is a competitive inhibitor of PI3-K, with an
inhibitory concentration of 50% (IC50) of 1.4 M.
7
LY294002 appears to be more specific than wortmannin,
with no effect on ERK, EGF receptor tyrosine kinase,
PI4-K, protein kinase C, protein kinase A, or S6 kinase.7
The 10 M dose was chosen as being slightly above the
IC50 to ensure complete PI3-K inhibition, and its effective-
ness was confirmed with Akt phosphorylation data.
PD98059 inhibits MEK1 (IC50 2 to 7 M) and MEK2
(IC50 50 M); it does not inhibit other MEKs or p70 S6
kinase in vitro.7
PD98059 had no effect on p38MAPK activation by uPA
in our vascular smooth muscle cells at 25 M (data not
shown), but it completely inhibited ERK 1/2 activation at
this dose.7
SB203580 is a pyridinyl imidazole that specifically in-
hibits the activated  and  isoforms of p38MAPK with an
IC50 600 nM. SB203580 demonstrates no inhibition of a
wide range of other kinases, including ERK 1/2, JNK,
ERK5, and several phosphatases in this dose range,7 al-
though it has been shown to activate Raf-1 (without effect
on MEK1/ERK) and to inhibit cytokine production.7
SB203580 had no effect on ERK 1/2 activation in our
vascular smooth muscle cells with 10M pretreatment (see
Results).
The EGF receptor kinase inhibitor AG1478 has been
shown to specifically inhibit ERK activation after angioten-
sin II (a Gq activator), Ca
2, or EGF stimulation in vascular
smooth muscle cells at 250 nM.7 The 10nM dose was used
to ensure complete inhibition of EGF receptor phosphor-
ylation.
[3H]Thymidine incorporation. Cells were allowed
to reach70% confluence as judged by microscopic exam-
ination. The cells were then placed in DMEM (Gibco) for
2 days to induce a quiescent state in the cells. The experi-
ments were initiated by adding 1 Ci/mL [3H]-thymidine(ICN, Irvine, Calif) with and without pharmacologic inhib-
itors and stimulating the cells with sc-uPA (10 nM). Incor-
poration of [3H]-thymidine into acid-precipitable material
was measured after a 24-hour incubation period (air plus
5% CO2 at 37°C). Stimulation was expressed as fold-
increase over starved cells (DMEM only), and the effects of
inhibitors were expressed as percentage of the stimulated
control.3
Cell proliferation. Culture wells (24-well cluster
dishes, Falcon) were inoculated with 3 mL growth medium
containing 5  104 cells, which were allowed to attach
overnight. Cell proliferation in response to sc-uPA (10 nM)
with and without pharmacologic inhibitors was deter-
mined. Cell counts were determined on days 1, 3, 5, and 7.
Cells from each well were removed by trypsinization and
the resultant suspension counted by using a Hemocytom-
eter (Hausser Scientific, Horsham, Pa). Proliferation was
expressed as the fold-increase over unstimulated cells
(DMEM only).3
Wound assay. Vascular smooth muscle cells were
grown to confluence in 60-mm2 dishes and then starved for
24 hours. Thereafter, each dish was divided into a 2  3
grid. With the use of a 1 to 200 L pipette tip, a linear
wound was made in each hemisphere of the dish. Under a
40 lens with an attached SPOT camera (Diagnostic In-
struments, Inc), images were taken of the intersections of
the linear wound and each grid line. This resulted in eight
fields per dish. Each field was measured at time 0 and at 24
hours. The area of each field was calculated using SPOT
Advanced software, and eight fields from each dish were
averaged. Trials with each reagent or inhibitor were per-
formed in six separate dishes, and the results were averaged.
Cells were then allowed to migrate over 24 hours at 37°C in
the presence of sc-uPA (10 nM) in the presence and ab-
sence of the inhibitors. Serum acted as a positive control
and both DMEM and DMEM with the respective inhibitor
were negative controls.3
Boyden chamber assay. Smooth muscle cell migra-
tion was assayed by a Boyden chamber method using a
48-well microchemotaxis chamber (Neuro Probe Inc,
Gaithersburg, Md) and polycarbonate filters (Poretics
Products, Livermore, Calif) with 10-m diameter pores as
previously described.8,9 Near confluent smooth muscle
cells that were starved for 24 hours, were trypsinized for 5
minutes, centrifuged, and resuspended in DMEM at a
concentration of 1.39  106 cells/mL. These cells were
then placed in equal concentration on the top of each filter.
Either serum-free DMEM, DMEM with uPA (10 nM), or
10% serum (positive control) were placed in the lower
compartment. In a second series of experiments, migration
in response to uPA was examined in the presence of the
inhibitors. Cells were pre-incubated for 1 hour with inhib-
itors and then applied to the upper compartment. The
chamber was incubated at 37°C under 5% CO2 for 6 hours.
The top portion of the filter was mechanically scraped and
the smooth muscle cells, which had migrated to the under
surface of the filter, were fixed in 100% methanol and
stained with Diff-Quick solution (Dade International Inc,
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counted at400 magnification to quantitate smooth mus-
cle cell migration. Migration was determined as the mean of
cells that had migrated per 400 field and expressed as a
percentage of DMEM control. All experiments were per-
formed in triplicate.
Western blotting. Cells were allowed to grow to 80%
confluence and starved for 48 hours. Cells were then stim-
ulated with each agonist alone and in the presence of
pharmacologic inhibitors, and harvested at time points
from 0 to 60 minutes as previously described.3 At each time
point, cells were washed twice in ice-cold PBS and mechan-
ically removed in the presence of ice-cold kinase buffer
(200 L; 25 mM HEPES [pH 7.5], 10% glycerol, 5 mM
ethylenediaminetetraacetic acid, 150 mM NaCl, 100 mM
benzamidine, 0.1% 2-mercaptoethanol, 1% Triton X-100,
1 mM pepstatin A, 2 mg/mL leupeptin, and 20 kallikrein
inhibitor units/mL aprotinin).
Protein determinations were performed using a bicin-
chonic acid assay (Pierce Chemical Co., Rockford, Ill) with
bovine serum albumen as the standard. Equal amounts of
protein lysates (10 g) were loaded onto a 10% polyacryl-
amide gel, separated by electrophoresis, and transferred to
nitrocellulose membranes (Biorad Laboratories, Rich-
mond, Calif). The membranes were blocked in 5% nonfat
milk. The blot was then immunoblotted with antibodies
against phosphorylated or total forms of each kinase, and
protein bands were visualized with enhanced chemilumi-
nescence (ECL, Amersham, Arlington Heights, Ill) using
the manufacturer’s protocols. Band intensity was measured
using Gel-Imaging software (Kodak, Rochester, NY).
Data and statistical analysis. All data are presented as
the mean  standard error of the mean; statistical differ-
ences between groups were tested with a Kruskal-Wallis
nonparametric test with post hoc Dunn’s multiple compar-
ison correction, where appropriate. P .05 was regarded as
significant and nonsignificant P values were expressed as P
	 NS.
RESULTS
Biologic responses. uPA induced a twofold increase
in cell migration (Fig 1, A) using the linear wound assay
and a threefold increase in DNA synthesis and cell prolifer-
ation (Fig 1, B). SB (MEK1, PD, and p38MAPK inhibitor)
blocked both DNA synthesis and cell proliferation in re-
sponse to sc-uPA, suggesting that both ERK1/2 and
p38MAPK are involved. Inhibition of MEK1/2 with PD,
but not inhibition of p38MAPK with SB, blocked sc-uPA-
induced cell migration, suggesting that ERK1/2 but not
p38MAPK is involved (Fig 1).
ERK and p38MAPK pathways. With the finding that
ERK1/2 and p38MAPK pathways are involved in uPA re-
sponses, we examined the activation of these kinases. uPA
induced time-dependent phosphorylation of MEK1/2,
ERK1/2, MKK3/6, and p38MAPK (Fig 2, A and B).
ERK1/2 activation could also be identified at 4 hours after
stimulation (data not shown). PTx prevented activation of
both ERK1/2 (2.5 vs 1.0-fold increase over DMEM at 15Fig 1. Single-chain urokinase plasminogen activator (sc-uPA)-
induced cell migration and cell proliferation. A, Cell migration. In
the wound assay (top panel) and in the Boyden chamber (bottom
panel), uPA (10 nM) induced migration, which was blocked by
inhibition of MEK1 with PD (PD98059, 10 M) but not by
inhibition of p38MAPK by SB (SB203580, 10M). Values are the
mean  standard error of the mean (SEM) percent decrease in
wound area after 24 hours in the wound assay and the percent
decrease in uPA-mediated migration in the Boyden chamber for six
experiments (*P  .05, **P  .01). B, Cell proliferation. The in
vitro [3H]-thymidine incorporation into the DNA (top panel) and
cell proliferation by manual counting (bottom panel) of cultured rat
vascular smooth muscle cells in response to uPA (10 nM) in the
presence and absence of the MEK1 inhibitor PD (10 M) and the
p38MAPK inhibitor SB (10 M). No responses were seen above
baseline (1) in the Dulbecco’s minimal essential medium controls
in both responses. Values are the mean  SEM percent of the
control for five experiments (*P  .05, **P  .01).
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p38MAPK (2.9- vs 1.2-fold increase over DMEM at 10
minutes; P .05) suggesting that a Gi coupled receptor is
involved.
In the presence of either PI3K inhibition with WN or
Ras inhibition with MA, there was a decrease in the phos-
phorylation of ERK1/2 (0.8-fold increase over DMEM for
WN and 1.1- fold increase over DMEM for MA; P  .05)
but not p38MAPK (2.3-fold increase over DMEM for WN
and 2.5-fold increase over DMEM for MA; P 
 .05),
suggesting that Ras and PI3K are involved in ERK1/2
activation but not p38MAPK activation. Both WN and MA
inhibited cell proliferation (44%  12% and 31%  6% of
uPA-induced [3H]thymidine incorporation for WN and
MA, respectively) and cell migration (25% 4% and 30%
3% of uPA-mediated migration for WN and MA, respec-
tively, in the Boyden chamber) in response to uPA.
As both PKC and Src are upstream regulators of both
kinases in many cell types, we examined the effect of their
inhibition on ERK1/2 and p38MAPK activation. GFX, the
PKC inhibitor but not the Src inhibitor PP2, inhibited
ERK1/2 (0.7-fold increase over DMEM for GFX, P .05
and 1.9-fold increase over DMEM for PP2, P
 .05). Both
GFX and PP2 inhibited p38MAPK activation (0.7-fold
increase over DMEM for GFX and a 1.2-fold increase over
DMEM for PP2; P  .05). In the presence of WN, PI3K
activity as measured by phosphorylation of Akt was inhib-
ited (data not shown).
Activation of the upstream kinase for ERK1/2,
MEK1/2, was inhibited by PTx (0.97-fold increase over
DMEM at 3 minutes), PP2 (0.9-fold increase over
DMEM; P .05), GFX (0.9-fold increase over DMEM; P
 .05), and MA (0.5-fold increase over DMEM; P .05),
but not by WN (2.1-fold increase over DMEM), suggest-
ing that Src, PKC, and Ras are involved but that it is
independent of PI3K.
Activation MKK3/6, the upstream kinase for
p38MAPK, was inhibited by PTx (0.8-fold increase over
DMEM at 5 minutes; P .05), PP2 (1.1-fold increase over
DMEM; P  .05), and GFX (1.1-fold increase over
DMEM; P  .05), but not by MA (2.2-fold increase over
DMEM; P 
 .05) or WN (1.7-fold increase over DMEM;
P
 .05), suggesting that Src and PKC are involved but that
MKK3/6 activation is independent of Ras and PI3K.
A role for EGF receptor. Incubation with the EGFR
inhibitor AG1478 resulted in a decrease in both cell prolif-
eration and migration in response to uPA (Fig 3, A and B).
uPA induced time-dependent EGFR phosphorylation, and
this activation was abrogated by incubation with the plas-
minogen activation inhibitors ε-aminocaproic acid and
aprotinin, and the metalloproteinase inhibitor GM6001
(Fig 3, C). In the presence of the EGFR inhibitor, ERK1/2
phosphorylation was reduced and PI3K-mediated Akt
phosphorylation was abolished, suggesting that EGFR-
mediated ERK1/2 activation may be PI3K-mediated (Fig
3, D and E). MEK1/2 activation was unaffected (2.2- vs.
1.7-fold increase over DMEM; uPA vs uPA  AG1478,
respectively; P 
 .05). Incubation with AG1478, theEGFR inhibitor, resulted in inhibition of the MKK3/
MKK6 and p38MAPK response, suggesting that EGFR is
involved in the activation of these kinases (Fig 3, D and  G).
DISCUSSION
uPA and processes of intimal injury. Plasminogen
activators and plasmin have been shown to have a signifi-
cant role in the development of intimal hyperplasia. After
injury to the rat carotid artery, plasminogen activator ex-
pression by vascular smooth muscle cells is differentially
regulated, with uPA present during mitogenesis and tissue
plasminogen activator (tPA) during migration.10 Other
more recent studies have shown that uPA is also involved in
cell migration.4,11 Over-expression of uPA and a deficiency
of PAI-1 in transgenic mice have been shown to promote
neointimal formation, whereas the absence of plasminogen
prevents lesion formation.12-14 uPA and plasmin genera-
tion are also important in the activation of matrix metallo-
proteinases (MMPs) on the cell surface.
The mechanisms whereby uPA induces proliferation
and migration are poorly understood. In the present study,
we have shown that uPA induces smooth muscle cell pro-
liferation through pathways mediated by ERK1/2 and
p38MAPK. Migration appears to be dependent on ERK1/2
activity alone. Activation of ERK1/2 occurs via two dis-
tinct G-protein-coupled pathways: the first is Ras-depen-
dent, PI3K-independent, and MEK1-mediated; the second
is MEK1-independent but EGFR-mediated and PI3K-de-
pendent. Src and PKC are upstream of MEK 1/2. p38MAPK
activation is dependent on EGFR activation, but is inde-
pendent of Ras and PI3K. This EGFR response is plasmin-
mediated and requires MMP activity.
ERK1/2 and uPA. ERK1/2 is one of the classic
pathways described for cell signaling. It is accepted that
ERK1/2 can be activated by Ras-Raf-MEK1/2 cascade.
However, in recent times it has also been demonstrated
that PKC- may act as a MEK kinase and will activate
MEK1/2 and ERK1/2. PKC- had been shown to be
upstream of Raf and to control the association of Ras with
Raf. Additionally, there are data to suggest that PI3K can
also initiate ERK1/2 independent of Ras activation. Mul-
tiple reports have shown that ERK1/2 activation is in-
volved in both migration and proliferation. However, the
difference between migration and proliferation appears to
be the finding that sustained ERK1/2 activation is required
for proliferation.15
We have previously shown that protease activity is
necessary for cell proliferation in response to uPA.3 uPA
binds to uPAR within a multiprotein complex and gener-
ates plasmin, which has been shown to interact with the
protease activated receptor PAR-1 (a Gi-coupled throm-
bin receptor), possibly using an annexin II molecule as a
cofactor.16 Thrombin and the thrombin receptor family
(PAR-1 to PAR-4) are the best characterized of the G-
protein-coupled protease activated receptors. These recep-
tors can activate both ERK1/2 and p38MAPK and can also
transactivate the EGFR, possibly through MMP-mediated
heparin-binding EGF release.17
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tion and that EGFR is involved in both cell migration and
proliferation. uPA-stimulated migration is due to the ami-
noterminal domain of the molecule (ATF) and is plasmin
independent.3,18,19 Binding of the ATF domain of uPA to
the uPAR receptor results in cleavage of uPAR into cell-
bound D1 containing the GPI tail and soluble D2/D3
fragments. D2/D3 then binds to FPRL-1, the low affinity
receptor of chemotactic peptide fMPL, to induce a Gi-
mediated migratory response.11 We have shown that the
ATF response is Gi but not Gq linked, and that the
response is ERK1/2 dependent but plasmin independent.3
In the present study, we confirmed that smooth muscle cell
migration is ERK1/2 dependent and demonstrated that
p38MAPK is not directly involved when the intact molecule
is examined. We have also demonstrated that EGFR-medi-
ated PI3K activation is involved in ERK1/2 activation
p38MAPK and uPA. The p38MAPK kinase pathway has
been implicated in the control of both cellular proliferation
and apoptosis20,21 and is considered to be activated by
cellular stress. Both G-protein–coupled receptors and re-
ceptor tyrosine kinases will induce p38MAPK activation. In
vitro, lysophosphatidic acid and PDGF-BB induce vascular
smooth muscle cell proliferation and phosphorylation of
both ERK1/2 and p38MAPK. The presence of the p38MAPK
inhibitor SB203580 can inhibit both cell proliferation and
phosphorylation of p38MAPK in a dose-dependent man-
ner.22 Our data suggest that uPA activates p38MAPK but
that p38MAPK is not involved in migration. This is interest-
ing, as p38MAPK interacts with the cytoskeleton through
heat shock proteins and there is evidence that heat shock
proteins are important in smooth muscle cell contraction, a
necessary mechanism for migration.23 SB203580 does not
effect ERK1/2 activation, and the presence of PD98059 (a
MEK1 inhibitor) has no effect on p38MAPK phosphoryla-
tion.22 At least four p38 isoforms have been identified,
p38, p38, p38, and p38. SB203580 is a competitive
inhibitor of the active form of p38 and p38 only.24-27 It
is therefore possible that the lack of an SB203580 effect is
due to isoform specificity.
There is evidence that alternative uPA-uPAR–initiated
signal transduction may occur, depending on integrin clus-
tering. In tumor cells, uPA-uPAR-51 complexes bind
fibronectin. Through a caveolin-independent mechanism,
the active uPA-uPAR-51-fibronectin fibril complex trig-
gers activation of the ERK pathway. The presence of fi-
bronectin fibrils along with cytoskeleton reorganization
will suppress p38MAPK.28 Thus, it is possible that accumu-
lation of different integrins within the uPAR multiprotein
complex, or simply the activation of different integrins, may
alter p38MAPK activation in our experiments. In our migra-
tion assay, we used confluent cells; whereas, in our cell
signaling and cell proliferation assays, we used nonconflu-
ent cells. However, similar results have been obtained (data
not shown) in the Boyden chamber, which does not use
confluent cells. These conditions may have altered integrins
within the multiprotein complexes but do not appear to
have affected the basic findings.  EGFR and uPA. We have demonstrated that
MKK3/6 and p38MAPK activation is controlled by Src and
PKC, and that the EGF receptor appears to be involved. In
addition, we demonstrated that EGFR activation requires
plasmin and MMP activity. Receptor transactivation is the
phenomenon whereby activation of a given receptor acti-
vates a heterologous receptor.29 This situation is com-
monly encountered in respect to G-protein–coupled recep-
tors (GPCR) and receptor-linked tyrosine kinases. ET-1,
lysophosphatidic acid, and thrombin induce rapid phos-
phorylation of the EGFR and suppression of this EGFR
Fig 2. Urokinase plasminogen activator (uPA) and mitogen-ac-
tivated protein kinase (MAPK). The phosphorylation of MEK1/2
(squares with broken line) and extracellular signal-regulated kinase
(ERK1/2) (open circles with solid line) in (A) and MAP kinase
kinase (MKK3/6) (squares with broken line) and p38MAPK (open
circles with solid line) in (B) in response to uPA (10 nM) over 30
minutes. Representative Western blots of the phosphorylated pro-
tein out to 60 minutes are shown above each graph. The ERK1/2
blot shows bands for both p42 and p44 and the p38MAPK blot
shows two bands at 38kD, representing two isoforms of p38MAPK
detected by the phospho-antibody. The values are mean  stan-
dard error of the mean fold-increase in phosphorylation over
control for three independent experiments. Total proteins blots
demonstrating equal loading on the gels were performed but are
not shown.activation leads to reduced ERK1/2 activation.
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proliferation and signaling. The in vitro [3H]-thymidine incorporation into DNA (A) and the migration over time in
scratch assays (B) in response to uPA (10nM) in the presence and absence of the EGFR inhibitor AG (AG1478, 10
nM). C, There was time dependent phosphorylation of the EGFR after exposure to uPA. D, The activation of EGFR
by uPA, and its abrogation in the presence of plasmin inhibitors, ε-aminocaproic acid and aprotinin and the matrix
metalloproteinases inhibitor (MMPI) GM6001. E, The activation of extracellular signal-regulated kinase (ERK1/2)
and p38MAPK in response to uPA (10 nM) in the presence and absence of the EGFR inhibitor AG1478 (10 nM).
MAPK, Mitogen-activated protein kinase. F and G, The activation of MAP kinase kinase (MKK3/6) and PI3K (as
measured by phosphorylation of akt) in response to uPA (10 nM) was markedly reduced in the presence of the EGFR
inhibitor (AG1478). The values with mean  standard error of the mean fold-increase over control for three
independent experiments are shown (*P  0.05; **P  .01).
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mechanism of GPCR-induced EGFR activation is a widely
accepted model of receptor-linked tyrosine kinases transac-
tivation. In this model, there is a sequence of three trans-
membrane signaling events: GPCR activation followed by
MMP activation, and subsequent activation of the EGFR
by the tethered ligand heparin-binding EGF or other latent
ligands of the EGFR. Activation of the MMP pathway has
been shown to involve one or more of the following signal-
ing molecules: Src, calcium, Pyk2, and PKC. Three separate
mechanisms may exist by which uPA-mediated plasmin
induces proliferation. Plasmin may activate MMP, which in
turn leads to EGFR-dependent MAPK activation that
would be G-protein independent.30,31
Inhibition of plasminogen activation decreases plasmin
and thus MMP activation. Plasmin has more recently been
shown to interact with PAR-1 (a thrombin receptor), pos-
sibly using an annexin molecule as a cofactor.16 Plasmin
appears to activate the receptor in a manner distinct from
the protease, thrombin.
Finally, the carboxy terminal of uPA may bind to a
distinct cell surface receptor independent of uPAR and
PAR-1, which remains to be identified. Activation of
PAR-1 may also lead to EGFR transactivation. Kalmes et
al17 have shown in smooth muscle cells that thrombin will
induce EGFR activation through an extracellular pathway
that involves MMP-mediated heparin-binding EGF release
and subsequent activation of the EGFR. From our data, it
appears that in the case of uPA, both plasmin and MMP are
involved in the activation of EGFR. Targeting a pivotal
cross talk receptor such as EGFR, which can be transacti-
vated by both G-protein-coupled receptors and receptor
tyrosine kinases, is an attractive molecular target. One
report in the classic rat carotid balloon injury model has
suggested that an antibody against EGFR will decrease
both smooth muscle cell proliferation and intimal hyper-
plasia after injury32
Role for uPAR. Migration of a range of cell types over
an artificial substratum in vitro is dependent on the binding
of uPA but not on its proteolytic activity. In the migrating
cell, uPAR is clustered on the leading edge.33 uPAR binds
both single-chain uPA and double-chain uPA, and cell
surface uPAR is efficiently cleaved by physiologic concen-
trations of uPA. Binding of uPA to uPAR promotes cellular
migration on vitronectin by a mechanism that requires
uPAR-initiated cell signaling and activation of Ras-depen-
dent ERK1/2 pathway,34 a pattern similar to our present
findings. These responses are pertussis-toxin sensitive, sug-
gesting the presence of Gi/G is associated with the
receptor.35 Upon the binding of the aminoterminal do-
main of uPA to uPAR, there is cleavage of uPAR into a
cell-bound D1 and soluble D2/D3 fragments. D2/D3
then binds to FPRL1, the low-affinity formic peptide re-
ceptor of fMPL, and induces a Gi-mediated response.36
uPAR also appears necessary for uPA-induced fibroblast
growth factor release from the matrix and the findings that
fibroblast growth factor is responsible for some of the
effects of uPA on cells.37,38 The present study did addressthe role of uPAR, however, our findings are consistent with
a role for uPAR in cell migration.
Clinical implications. The universal response of a
blood vessel to injury is chronic wound healing, which
includes the development of intimal hyperplasia through
smooth muscle cell migration and proliferation, and subse-
quent remodeling of the vessel wall. This can lead to
luminal narrowing in 30% of patients undergoing angio-
plasty. Neointimal formation is the principal cause of in-
stent restenosis. Elevated uPA and decreased PAI-1 levels
are predictors for restenosis.1
Whereas many previous studies have focused on the
multiple mechanical, humoral, and cellular elements that
induce smooth muscle cell responses (either migration or
proliferation), molecular therapeutics focus on key choke
points within the cell that can be used to inhibit these
responses. The present study examined the pathways that
allow uPA, a plasminogen activator known to be involved
in tissue remodeling after injury, to induce both smooth
Fig 4. Proposed urokinase plasminogen activator (uPA) interac-
tion with mitogen-activated protein kineases (MAPKs) and the
role of epidermal growth factor receptor (EGFR. Flow diagram
illustrates the proposed pathways by which uPA may differentially
activate MAPK and induce migration or proliferation. uPA induces
smooth muscle cell proliferation through extracellular signal-reg-
ulated kinase (ERK1/2) and p38MAPK-mediated pathways and cell
migration through an ERK1/2-mediated pathway. Activation of
ERK1/2 occurs via two distinct G-protein coupled receptor
(GPCR) pathways: one of which is Ras-dependent, phosphatidyl-
inositol 3= kinase (PI3K)-independent, MEK1-mediated and a
second, which is Ras and MEK1 independent, but EGFR- and
PI3K-mediated. Protein kinase C (PKC) may act as a MEK1
activator independent of either Ras or PI3K. p38MAPK activation is
G-protein coupled and is dependent on plasmin and matrix met-
alloproteinases (MMP) activation, which results in EGFR activa-
tion; this pathway is independent of Ras and PI3K. These findings
also suggest that a plasmin- and MMP-mediated transactivation
process is occurring. Differential activation of ERK1/2 and
p38MAPK by uPA allows for two distinct biologic responses, which
appears to require EGFR transactivation.muscle cell migration and cell proliferation. The study
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responses through more than one signaling pathway, in
part, by transactivation of a nearby receptor for an unre-
lated ligand, namely EGFR. Blockade of EGFR can inhibit
both cell migration and proliferation induced by uPA. This
is the first description of cross talk between uPA and EGFR
in vascular smooth muscle cells.
Acute arterial occlusions and graft occlusions are often
targeted for therapeutic thrombolysis. Both uPA and tPA
induce plasmin activity. The present data support a role for
plasmin activity in smooth muscle cell proliferation and
EGFR activation. Targeting a pivotal receptor such as
EGFR, which can be transactivated by both G-protein-
coupled receptors and receptor tyrosine kinases, is an at-
tractive molecular target to separate out the benefit of
thrombolysis with the possible negative effects inferred by
the stimulation of smooth muscle cell proliferation and
thus provides a hypothetical means to control restenosis.
Conclusion. uPA induces smooth muscle cell prolif-
eration through ERK1/2- and p38MAPK- mediated path-
ways (Fig 4). Migration appears to be dependent on
ERK1/2 activity alone. uPA induces activation of the
EGFR. Activation of ERK1/2 occurs via two distinct G-
protein–coupled pathways. One is Ras-dependent, PI3K-
independent, and MEK1-mediated; the second is Ras and
MEK1-independent but EGFR- and PI3K-mediated.
p38MAPK activation is dependent on plasmin activation,
G-protein coupling, PKC, and EGFR activation but is
independent of Ras and PI3K. Plasmin and MMP are
involved in this transactivation process. Differential activa-
tion of ERK1/2 and p38MAPK by uPA allows for two
distinct biologic responses and requires EGFR transactiva-
tion.
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